Therapeutic Class Report Overview - Rituxan Biosimilar - 2 views
-
Olivia Lopez on 15 Jan 14In this report, we have analyzed the market opportunity of Rituximab Biosimilar and its competitive landscape. We believe that despite several clinical setbacks in the Rituxan biosimilars pipeline, they could pose a challenge to Rituximab by 2018.